Featured Publications
2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients
Forrest JK, Deeb GM, Yakubov SJ, Rovin JD, Mumtaz M, Gada H, O'Hair D, Bajwa T, Sorajja P, Heiser JC, Merhi W, Mangi A, Spriggs DJ, Kleiman NS, Chetcuti SJ, Teirstein PS, Zorn GL, Tadros P, Tchétché D, Resar JR, Walton A, Gleason TG, Ramlawi B, Iskander A, Caputo R, Oh JK, Huang J, Reardon MJ. 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. Journal Of The American College Of Cardiology 2022, 79: 882-896. PMID: 35241222, DOI: 10.1016/j.jacc.2021.11.062.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEvolut Low Risk trialLow-risk trialsAortic valve replacementPrimary endpointRisk trialsCause mortalityValve replacementTranscatheter Versus Surgical Aortic Valve ReplacementLow surgical risk patientsSurgical aortic valve replacementIndependent clinical events committeeEchocardiographic core laboratoryKaplan-Meier ratesSevere aortic stenosisClinical events committeeLow-risk patientsCause mortality ratesSelf-expanding valvesDisabling strokeEchocardiographic outcomesSurgical AVRTAVR groupSurgery groupAdverse eventsTranscatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis
Forrest JK, Ramlawi B, Deeb GM, Zahr F, Song HK, Kleiman NS, Chetcuti SJ, Michelena HI, Mangi AA, Skiles JA, Huang J, Popma JJ, Reardon MJ. Transcatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis. JAMA Cardiology 2020, 6: 50-57. PMID: 33031491, PMCID: PMC7542521, DOI: 10.1001/jamacardio.2020.4738.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementBicuspid aortic valve stenosisAortic valve replacementAortic valve stenosisLow-risk patientsDevice success rateValve replacementValve stenosisCause mortalityRandomized trialsAmerican Heart Association/American CollegeSevere bicuspid aortic valve stenosisHigh device success rateLow surgical risk patientsPrespecified primary end pointPrimary efficacy end pointEnd pointBicuspid aortic stenosisMean AV gradientThoracic Surgeons scoreEfficacy end pointPrimary end pointLow surgical riskMild paravalvular leakNew permanent pacemakerTranscatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry
Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, Jilaihawi H, Liu F, Reardon MJ. Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry. JACC Cardiovascular Interventions 2020, 13: 1749-1759. PMID: 32473890, DOI: 10.1016/j.jcin.2020.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisBicuspid Aortic Valve DiseaseFemaleHeart Valve ProsthesisHemodynamicsHumansMaleMiddle AgedPostoperative ComplicationsProsthesis DesignRecovery of FunctionRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsAortic valve stenosisBicuspid aortic valve stenosisTranscatheter aortic valve replacementEvolut PRO valveAortic valve replacementValve stenosisTVT RegistryCause mortalityValve replacementEvolut RBicuspid valveBicuspid Versus Tricuspid Aortic ValvesSTS/ACC TVT RegistryThoracic Surgeons/American CollegeTricuspid aortic valve stenosisCardiology TVT (Transcatheter Valve Therapy) RegistryTricuspid aortic stenosisRate of strokeSelf-expanding valvesLow complication rateTricuspid aortic valveAcceptable safety outcomesCardiac comorbiditiesEchocardiographic outcomesAortic stenosisEarly Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap
Forrest JK, Mangi AA, Popma JJ, Khabbaz K, Reardon MJ, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL, Brown J, Kipperman R, Saul S, Qiao H, Oh JK, Williams MR. Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC Cardiovascular Interventions 2018, 11: 160-168. PMID: 29348010, DOI: 10.1016/j.jcin.2017.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisCause of DeathEchocardiographyFemaleHeart Valve ProsthesisHemodynamicsHumansMaleMitral Valve InsufficiencyPericardiumProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsSelf-expanding transcatheter aortic valveSevere symptomatic aortic stenosisEvolut PRO valveSymptomatic aortic stenosisTranscatheter aortic valveAortic stenosisParavalvular leakAortic valveValve Academic Research Consortium-2 criteriaIndependent echocardiographic core laboratoryTranscatheter aortic valve replacementTranscatheter aortic valve systemEchocardiographic core laboratoryPrimary safety endpointPrimary efficacy endpointRemainder of patientsAortic valve replacementProportion of patientsProsthetic valve regurgitationSupra-annular valveEffective orifice areaDisabling strokeCause mortalityEfficacy endpointSafety endpointINITIAL USE OF THE EVOLUT PRO SELF-EXPANDING TRANSCATHETER AORTIC VALVE
Forrest J, Mangi A, Popma J, Khabbaz K, Reardon M, Kleiman N, Yakubov S, Watson D, Kodali S, George I, Tadros P, Zorn G, Brown J, Kipperman R, Staniloae C, Williams M. INITIAL USE OF THE EVOLUT PRO SELF-EXPANDING TRANSCATHETER AORTIC VALVE. Journal Of The American College Of Cardiology 2017, 69: 1288. DOI: 10.1016/s0735-1097(17)34677-6.Peer-Reviewed Original ResearchPropensity-Matched Outcomes Comparing TAVR in Bicuspid vs Surgery in Tricuspid Aortic Valve Stenosis
Deeb G, Yakubov S, Reardon M, Ramlawi B, Chetcuti S, Kleiman N, Zahr F, Song H, Gada H, Mumtaz M, Ito S, Huang J, Forrest J. Propensity-Matched Outcomes Comparing TAVR in Bicuspid vs Surgery in Tricuspid Aortic Valve Stenosis. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 2: 100525. PMID: 39132531, PMCID: PMC11307701, DOI: 10.1016/j.jscai.2022.100525.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementSurgical aortic valve replacementAortic valve stenosisTricuspid aortic valve stenosisBicuspid aortic valve stenosisAortic valve replacementSAVR patientsValve replacementValve stenosisEvolut Low Risk trialIndependent clinical events committeeLow-risk trialsSerious adverse eventsSevere aortic regurgitationClinical events committeeLow surgical riskLow-risk patientsIndependent core laboratoryEffective orifice areaTAVR groupValve gradientAdverse eventsAortic regurgitationSurgical riskEvents committee3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
Forrest J, Deeb G, Yakubov S, Gada H, Mumtaz M, Ramlawi B, Bajwa T, Teirstein P, DeFrain M, Muppala M, Rutkin B, Chawla A, Jenson B, Chetcuti S, Stoler R, Poulin M, Khabbaz K, Levack M, Goel K, Tchétché D, Lam K, Tonino P, Ito S, Oh J, Huang J, Popma J, Kleiman N, Reardon M, Investigators L, Sorajja P, Byrne T, Kirshner M, Bajwa T, Crouch J, Coselli J, Silva G, Hebeler R, Stoler R, Islam A, Rousou A, Poulin M, Khabbaz K, Bladergroen M, Fail P, Netherland D, Lam K, Tonino W, Sudre A, Berthoumieu P, Tchétché D, Khalili H, Hughes G, Harrison J, De A, Tsau P, van Mieghem N, Larbalestier R, Yong G, Agarwal S, Martin W, Park S, Kleiman N, Reardon M, Mohammadi S, Rodes-Cabau J, Sparling J, Elkins C, Ganzel B, Matthews R, Starnes V, Ando K, Chevalier B, Farge A, DeFrain M, Muppala M, Combs W, Bagur R, Chu M, Fontana G, Dev V, Leya F, Tuchek J, Inglessis I, Jassar A, Piazza N, Lacappelle K, Steinberg D, Katz M, Wang J, Kozina J, Slachman F, Merritt R, Chawla A, Jensen B, Alvarez J, Gooley R, Smith J, Ibrahim R, Cartier R, Rovin J, Fujita T, Rutkin B, Yakubov S, Song H, Zahr F, Miyagawa S, Rajagopal V, Kauten J, Gada H, Mumtaz M, Bhindi R, Brady P, Batra S, Davis T, Iskander A, Heimansohn D, Hermiller J, Takamisawa I, Haldis T, Yamazaki S, Teirstein P, Tada N, Saito S, Merhi W, Leung S, Muller D, Heijmen R, Petrossian G, Robinson N, Knight P, Ling F, Radhakrishnan S, Fremes S, Lehr E, Gafoor S, Noel T, Walton A, Resar J, Adams D, Sharma S, Lilly S, Tadros P, Zorn G, Dauerman H, Ittleman F, Horlick E, Feindel C, Welt F, Sharma V, Markowitz A, Carroll J, Fullerton D, Griffith B, Gupta A, de Marchena E, Salerno T, Chetcuti S, Deeb G, Sultan I, Goel K, Pasupati S, Kon N, Zhao D, Ramlawi B, Forrest J. 3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. Journal Of The American College Of Cardiology 2023, 81: 1663-1674. PMID: 36882136, DOI: 10.1016/j.jacc.2023.02.017.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementLow-risk patientsCause mortalityPrimary endpointParavalvular regurgitationValve replacementEvolut Low Risk trialLow surgical risk patientsSurgical aortic valve replacementGreater paravalvular regurgitationLow-risk trialsData comparing outcomesLow-risk studiesSupra-annular valveEchocardiographic outcomesSecondary endpointsSurgery groupTAVR patientsRisk patientsSurgery patientsAortic stenosisPacemaker placementTreatment armsMean age
2025
Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients An Updated Meta-Analysis of Randomized Controlled Trials
Reddy R, Howard J, Mack M, Reardon M, Jørgensen T, Hørsted Thyregod H, Toff W, Van Mieghem N, Vora A, Makkar R, Kapadia S, Forrest J, Leon M, Ahmad Y. Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients An Updated Meta-Analysis of Randomized Controlled Trials. Journal Of The American College Of Cardiology 2025, 85: 926-940. PMID: 40044297, DOI: 10.1016/j.jacc.2024.12.031.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementLower-risk patientsAortic valve replacementPooled survival analysisValve replacementIndividual participant dataPairwise meta-analysesFollow-upMeta-analysis of randomized controlled trialsLonger-term clinical outcomesReduced hazard of deathSevere aortic stenosisFixed effect assumptionsComposite of deathLonger-term follow-upAll-cause deathMean survival time modelsMeta-analysesHazard of deathRate of strokeRandomized controlled trialsSurvival time modelFrailty termProportional odds modelImpact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk
Yakubov S, Van Mieghem N, Oh J, Ito S, Grubb K, O’Hair D, Forrest J, Gada H, Mumtaz M, Deeb G, Tang G, Rovin J, Jain R, Windecker S, Skelding K, Kleiman N, Chetcuti S, Dedrick A, Boatman S, Popma J, Reardon M. Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. Journal Of The American College Of Cardiology 2025 DOI: 10.1016/j.jacc.2025.02.009.Peer-Reviewed Original ResearchBioprosthetic valve dysfunctionRandomized controlled trialsRandomized controlled trial patientsClinical outcomesAssociated with increased 5-year all-cause mortalityWorsening heart failureContinued Access StudyAll-cause mortalityPost hoc analysisPooled randomized controlled trialsIntermediate riskPivotal trialsPrimary endpointAortic valve performanceValve dysfunctionSurgery patientsHeart failureValve diseaseTAVI patientsSupra-annularSurgeryCardiovascular mortalityClinical importancePatientsControlled trialsEffect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
Shah T, Zhang Z, Shah H, Fanaroff A, Nathan A, Parise H, Lutz J, Sugeng L, Bellumkonda L, Redfors B, Omerovic E, Petrie M, Vora A, Fiorilli P, Kobayashi T, Ahmad Y, Forrest J, Giri J, Herrmann H, Lansky A. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC Cardiovascular Interventions 2025, 18: 738-748. PMID: 39985508, DOI: 10.1016/j.jcin.2024.11.036.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsCotransporter-2 inhibitorsAortic stenosisEffects of sodium-glucose cotransporter-2 inhibitorsProgression of aortic stenosisBaseline AS severityAssociated with slower progressionEchocardiographic follow-upRetrospective electronic medical record dataAortic valve sclerosisDisease-related morbidityChronic kidney diseaseSGLT2i usageRates of diabetesSevere ASAS severityEjection fractionFollow-upPrimary outcomeGt;1 yearKidney diseaseMedical record dataYale New Haven Health SystemPatientsObservational studyPathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening
Sato Y, Torii S, Kawai K, Yahagi K, Kutyna M, Kawakami R, Konishi T, Vozenilek A, Jinnouchi H, Sakamoto A, Mori H, Cornelissen A, Mori M, Tanaka T, Sekimoto T, Kutys R, Ghosh S, Forrest J, Reardon M, Romero M, Kolodgie F, Virmani R, Finn A. Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening. Circulation Cardiovascular Interventions 2025, 18: e014523. PMID: 39965045, PMCID: PMC11827688, DOI: 10.1161/circinterventions.124.014523.Peer-Reviewed Original ResearchConceptsHypoattenuated leaflet thickeningLeaflet thickeningHistological findingsClinical trialsEvaluate histological findingsAortic valve proceduresSelf-expanding transcatheter aortic valvesAortic bioprosthetic valvesAortic valve leafletsInfective endocarditisValve proceduresTranscatheter aortic valveValve thrombosisAortic bioprosthesesSurgical explantationInflammation scoreAortic valveAcute thrombusImplant durationOrganized thrombusBioprosthetic valvesDay groupLeaflet thrombosisThrombusValve leafletsBeyond Echo-Derived Gradients Balloon-Expandable Valve Outcomes in Small Annuli Patients
Vora A, Forrest J, Krishnaswamy A. Beyond Echo-Derived Gradients Balloon-Expandable Valve Outcomes in Small Annuli Patients. JACC Cardiovascular Interventions 2025, 18: 518-520. PMID: 40010920, DOI: 10.1016/j.jcin.2024.12.007.Peer-Reviewed Original Research
2024
Inflow-to-Outflow Stent Frame Expansion, Ellipticity, and Decoupling in Evolut TAVR: Implications for Mid-term Hemodynamic Performance
Puri R, Spencer J, Tchétché D, Van Mieghem N, Forrest J, Reardon M, Sanchez J, Caballero A, Blanke P, Leipsic J, Sorajja P, Deeb G, Fukuhara S, Lucas L, Oyekunle T, Tang G. Inflow-to-Outflow Stent Frame Expansion, Ellipticity, and Decoupling in Evolut TAVR: Implications for Mid-term Hemodynamic Performance. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 4: 102448. PMID: 40061419, PMCID: PMC11887556, DOI: 10.1016/j.jscai.2024.102448.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementTranscatheter aortic valveFrame deformationHypoattenuated leaflet thickeningEffective orifice areaFrame expansionHemodynamic performanceLeaflet thickeningSelf-expanding transcatheter aortic valve replacementLeaflet regionsOrifice areaDays post-TAVRAortic valve replacementNative aortic annulusInflow geometriesEllipticity ratioVariable ellipticityComputed tomography imagesAortic annulusValve replacementParavalvular regurgitationAnnular levelPost-TAVRAortic valveTranscatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials
Reddy R, Howard J, Reardon M, Thyregod H, Jorgensen T, Toff W, Forrest J, Leon M, Ahmad Y. Transcatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials. European Heart Journal 2024, 45: ehae666.2456. DOI: 10.1093/eurheartj/ehae666.2456.Peer-Reviewed Original ResearchLower-risk patientsIndividual patient dataFollow-upNo significant differenceClinical outcomesPairwise random-effects meta-analysesNew-onset atrial fibrillationLong-term clinical outcomesSurgical aortic valve replacementKaplan-Meier survival curvesMeta-analysis of randomised controlled trialsLow-surgical riskMeta-analysesAortic valve reinterventionReconstructed individual patient dataLow surgical riskAortic valve replacementFollow-up durationSevere aortic stenosisMeta-analysisSignificant differenceCox proportional hazards regressionComposite of deathKaplan-Meier plotsLonger-term follow-upThree-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients
Modine T, Tchétché D, Van Mieghem N, Deeb G, Chetcuti S, Yakubov S, Sorajja P, Gada H, Mumtaz M, Ramlawi B, Bajwa T, Crouch J, Teirstein P, Kleiman N, Iskander A, Bagur R, Chu M, Berthoumieu P, Sudre A, Adrichem R, Ito S, Huang J, Popma J, Forrest J, Reardon M. Three-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients. Circulation Cardiovascular Interventions 2024, 17: e014018. PMID: 39421943, PMCID: PMC11573113, DOI: 10.1161/circinterventions.124.014018.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementSelf-expanding transcatheter aortic valve replacementLow-risk patientsPatients aged <Society of Thoracic Surgeons Predicted Risk of MortalityRandomized to TAVRRate of severe prosthesis-patient mismatchSupra-annularThoracic Surgeons Predicted Risk of MortalityEvolut Low Risk TrialIncidence of disabling strokePatients treated with transcatheter aortic valve replacementRate of valve thrombosisSevere prosthesis-patient mismatchPatients treated with surgeryDisabling strokeIncidence of pacemaker implantationSevere aortic stenosis patientsRates of all-cause mortalityProsthesis-patient mismatchAortic valve replacementSevere aortic stenosisAortic stenosis patientsPatients to treatmentAll-cause mortalityTCT-187 Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
Shah T, Shah H, Zhang Z, Fanaroff A, Nathan A, Parise H, Lutz J, Sugeng L, Bellumkonda L, Redfors B, Omerovic E, Petrie M, Vora A, Fiorilli P, Kobayashi T, Ahmad Y, Forrest J, Giri J, Herrmann H, Lansky A. TCT-187 Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. Journal Of The American College Of Cardiology 2024, 84: b10. DOI: 10.1016/j.jacc.2024.09.223.Peer-Reviewed Original ResearchTCT-149 Institutional Volume and Failure to Rescue in Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry
Sreenivasan J, Vemulapalli S, Kosinski A, Sherwood M, Cohen D, Forrest J, Ahmad Y, Julien H, Kaneko T, Vora A. TCT-149 Institutional Volume and Failure to Rescue in Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. Journal Of The American College Of Cardiology 2024, 84: b367. DOI: 10.1016/j.jacc.2024.09.1057.Peer-Reviewed Original ResearchFour-Year Outcomes After Transcatheter or Contemporary Surgical Aortic Valve Replacement from the Evolut Low Risk Trial
Ramlawi B, Deeb G, Mumtaz M, Bajwa T, Rovin J, Yakubov S, Jung Y, Reardon M, Forrest J. Four-Year Outcomes After Transcatheter or Contemporary Surgical Aortic Valve Replacement from the Evolut Low Risk Trial. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 39181441, DOI: 10.1016/j.jtcvs.2024.08.023.Peer-Reviewed Original ResearchSurgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis
Grubman D, Lansky A, Dwyer M, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Leon M, Forrest J, Vora A, Parise H, Messé S. Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis. Cardiovascular Revascularization Medicine 2024, 65: 80. DOI: 10.1016/j.carrev.2024.04.179.Peer-Reviewed Original Research800.01 Redo-TAVR With the Supra-Annular, Self-Expanding Evolut Platform: Insights from a Multi-Center Real-World Registry
Rogers T, Bapat V, Chetcuti S, Dauerman H, Forrest J, Grubb K, Htun W, Puri R, Reardon M, Tang G, Vora A, Yakubov S, Eisenberg R, Attizzani G. 800.01 Redo-TAVR With the Supra-Annular, Self-Expanding Evolut Platform: Insights from a Multi-Center Real-World Registry. Cardiovascular Revascularization Medicine 2024, 65: 77. DOI: 10.1016/j.carrev.2024.04.173.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply